激素受体阳性乳腺癌靶向治疗进展

夏雯; 王树森

doi:10.3969/j.issn.1000-8179.2017.13.008

激素受体阳性乳腺癌靶向治疗进展

doi: 10.3969/j.issn.1000-8179.2017.13.008

夏雯,
王树森^,

中山大学肿瘤防治中心内科，华南肿瘤学国家重点实验室，协同医学创新中心（广州市510060）

基金项目:

本文课题受国家自然科学基金联合基金项目 U1601224

详细信息

作者简介:
夏雯专业方向为乳腺癌的个体化诊治、全程管理及遗传咨询。E-mail：xiawen@sysucc.org.cn

王树森教授，医学博士，硕士生导师。现任中山大学肿瘤医院内科乳腺病区主任，主任医师。2010年在Memorial Sloan Ketttering Cancer Center学习。主要从事乳腺癌的化疗、内分泌治疗及靶向治疗。兼任广东省胸部肿瘤防治研究会乳腺癌专业委员会主任委员，广东省抗癌协会乳腺癌专业委员会副主任委员，广东省抗癌协会化疗专业委员会副主任委员，中国研究型医院学会乳腺专业委员会副主任委员，中国抗癌协会肿瘤临床化疗专业委员会委员，中国抗癌协会肿瘤临床化疗专业委员会青年委员会副主任委员。曾主持2项国家自然科学基金面上项目研究。发表SCI论文43篇（第一/通讯作者22篇）。作为PI参与多项国内外多中心临床研究

通讯作者:
王树森; E-mail: wangshs@sysucc.org.cn

计量
- 文章访问数: 72
- HTML全文浏览量: 21
- PDF下载量: 3
- 被引次数: 0
出版历程
- 收稿日期: 2017-01-04
- 修回日期: 2017-05-16
- 刊出日期: 2017-07-15

Advances of target therapy in hormone-receptor-positive breast cancer

XIA Wen,
WANG Shusen^,

Department of Medical Oncology, Sun Yat-sen University Cancer Center State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Guangzhou, 510060, China

Funds:

Joint Funds of the National Natural Science Foundation of China U1601224

More Information

Corresponding author: Shusen WANG; E-mail: wangshs@sysucc.org.cn

摘要

摘要: 内分泌治疗是激素受体阳性乳腺癌的主要治疗手段。内分泌耐药是这部分患者肿瘤复发或进展的主要原因。近期研究发现一系列导致激素受体阳性乳腺癌不依赖雌激素的抵抗机制，开发出相应的靶向治疗药物，其中包括细胞周期蛋白依赖性激酶4/6抑制剂、mTOR抑制剂、表皮生长因子受体抑制剂、抗血管生成药物、组蛋白去乙酰化酶抑制剂、成纤维细胞生长因子受体抑制剂、胰岛素样生长因子受体抑制剂，以及免疫检查点抑制剂等。这些药物被用于阻断耐药通路并提高内分泌治疗疗效，其中已经被批准上市的靶向药物有依维莫司和palbociclib。本文将对内分泌联合靶向治疗的药物研究进展进行综述。
- 激素受体阳性乳腺癌 /
- 内分泌治疗 /
- 靶向治疗
Abstract: Hormone therapy is a major treatment option for hormone-receptor-positive (HR+) breast cancer. Resistance to hormone therapy is the major reason for disease recurrence and progression. Recent studies have identified several resistance mechanisms that lead to the estrogen-independent growth of HR+ breast cancer and were exploited to develop novel target drugs, including cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitor, mammalian target of rapamycin (mTOR) inhibitor, epidermal growth factor receptor family inhibitor, vascular endothelial growth factor inhibitor, histone deacetylase inhibitor, fibroblast growth factor receptor inhibitor, insulinlike growth factor receptor inhibitor, and checkpoint inhibitor. These inhibitors are being developed to block resistance pathways and improve the efficacy of hormonal therapy. Among these drugs, the mTOR inhibitor everolimus and the CDK4/6 inhibitor palbociclib are currently approved in the United States to treat metastatic HR+ breast cancer. In this study, we summarize the frontier advances in the combination of hormone and target therapies.
- hormone-receptor-positive breast cancer /
- hormone therapy /
- target therapy

HTML全文

参考文献(30)

[1]	Anderson WF, Chatterjee N, Ershler WB, et al. Estrogen receptor breast cancer phenotypes in the surveillance, epidemiology, and end results database[J]. Breast Cancer Res Treat, 2002, 76(1):27-36. doi: 10.1023/A:1020299707510
[2]	Cardoso F, Costa A, Senkus E, et al. 3rd ESO-ESMO International Consensus Guidelines for advanced breast cancer (ABC 3)[J]. Ann Oncol, 2016:w544. https://www.ncbi.nlm.nih.gov/pubmed/28177437/
[3]	Rugo HS, Rumble RB, Burstein HJ. Endocrine therapy for hormone receptor positive metastatic breast cancer: american society of clinical oncology guideline summary[J]. J Oncol Pract, 2016, 12(6):583-587. doi: 10.1200/JOP.2016.012914
[4]	Xu B, Hu X, Jiang Z, et al. National consensus in China on diagnosis and treatment of patients with advanced breast cancer[J]. Ann Transl Med, 2015, 3(17):242. https://www.researchgate.net/publication/284719717_National_consensus_in_China_on_diagnosis_and_treatment_of_patients_with_advanced_breast_cancer
[5]	Gradishar WJ, Anderson BO, Balassanian R, et al. Invasive breast cancer version 1.2016, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2016, 14(3):324-354. doi: 10.6004/jnccn.2016.0037
[6]	Finn RS, Crown JP, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study[J]. Lancet Oncol, 2015, 16(1):25-35. doi: 10.1016/S1470-2045(14)71159-3
[7]	Finn RS, Martin M, Rugo HS, et al. Palbociclib and Letrozole in Advanced Breast Cancer[J]. N Engl J Med, 2016, 375(20):1925-1936. doi: 10.1056/NEJMoa1607303
[8]	Ozaki A, Tanimoto T, Saji S. Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer[J]. N Engl J Med, 2015, 373(17):1672-1673. doi: 10.1056/NEJMc1510345
[9]	Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as first-Line therapy for HR-positive, advanced breast cancer[J]. N Engl J Med, 2016, 375(18):1738-1748. doi: 10.1056/NEJMoa1609709
[10]	Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer[J]. Nat Rev Cancer, 2002, 2(7):489-501. doi: 10.1038/nrc839
[11]	Bachelot T, Bourgier C, Cropet C, et al. Randomized phase Ⅱ trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study[J]. J Clin Oncol, 2012, 30(22):2718-2724. doi: 10.1200/JCO.2011.39.0708
[12]	Massarweh S, Romond E, Black EP, et al. A phase Ⅱ study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure [J]. Breast Cancer Res Treat, 2014, 143(2):325-332. doi: 10.1007/s10549-013-2810-9
[13]	Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer[J]. N Engl J Med, 2012, 366(6):520-529. doi: 10.1056/NEJMoa1109653
[14]	Krop IE, Mayer IA, Ganju V, et al. Pictilisib for oestrogen receptorpositive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial[J]. Lancet Oncol, 2016, 17(6):811-821. doi: 10.1016/S1470-2045(16)00106-6
[15]	Kaufman B, Mackey JR, Clemens MR, et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase Ⅲ TAnDEM study[J]. J Clin Oncol, 2009, 27(33): 5529-5537. doi: 10.1200/JCO.2008.20.6847
[16]	Finn RS, Press MF, Dering J, et al. Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in HER2-negative or unknown metastatic breast cancer[J]. J Clin Oncol, 2009, 27(24):3908-3915. doi: 10.1200/JCO.2008.18.1925
[17]	Swain SM, Baselga J, Kim S B, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer[J]. N Engl J Med, 2015, 372(8):724-734. doi: 10.1056/NEJMoa1413513
[18]	Yardley DA, Ismail-Khan RR, Melichar B, et al. Randomized phase Ⅱ, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor[J]. J Clin Oncol, 2013, 31(17):2128-2135. doi: 10.1200/JCO.2012.43.7251
[19]	Liang Y, Hyder SM. Proliferation of endothelial and tumor epithelial cells by progestin-induced vascular endothelial growth factor from human breast cancer cells: paracrine and autocrine effects[J]. Endocrinology, 2005, 146(8):3632-3641. doi: 10.1210/en.2005-0103
[20]	Manders P, Beex LV, Tjan-Heijnen VC, et al. Vascular endothelial growth factor is associated with the efficacy of endocrine therapy in patients with advanced breast carcinoma[J]. Cancer, 2003, 98(10):2125-2132. doi: 10.1002/(ISSN)1097-0142
[21]	Martin M, Loibl S, von Minckwitz G, et al. Phase Ⅲ trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the letrozole/fulvestrant and avastin (LEA) study[J]. J Clin Oncol, 2015, 33(9):1045-1052. doi: 10.1200/JCO.2014.57.2388
[22]	Dickler MN, Barry WT, Cirrincione CT, et al. PhaseⅢ trial evaluating letrozole as first-line endocrine therapy with or without bevacizumab for the treatment of postmenopausal women with hormone receptorpositive advanced-stage breast cancer: CALGB 40503 (Alliance)[J]. J Clin Oncol, 2016, 34(22):2602-2609. doi: 10.1200/JCO.2015.66.1595
[23]	Zhang Y, Moerkens M, Ramaiahgari S, et al. Elevated insulin-like growth factor 1 receptor signaling induces antiestrogen resistance through the MAPK/ERK and PI3K/Akt signaling routes[J]. Breast Cancer Res Treat, 2011, 13(3):R52. doi: 10.1186/bcr2883
[24]	Fagan DH, Yee D. Crosstalk between IGF1R and estrogen receptor signaling in breast cancer[J]. J Mammary Gland Biol, 2008, 13(4):423-429. doi: 10.1007/s10911-008-9098-0
[25]	Robertson JF, Ferrero JM, Bourgeois H, et al. Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial[J]. Lancet Oncol, 2013, 14(3):228-235. doi: 10.1016/S1470-2045(13)70026-3
[26]	Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer[J]. Nat Rev Cancer, 2010, 10(2):116-129. doi: 10.1038/nrc2780
[27]	Turner N, Pearson A, Sharpe R, et al. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer [J]. Cancer Res, 2010, 70(5):2085-2094. doi: 10.1158/0008-5472.CAN-09-3746
[28]	Andre F, Bachelot T, Campone M, et al. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer[J]. Clin Cancer Res, 2013, 19(13):3693-3702. doi: 10.1158/1078-0432.CCR-13-0190
[29]	Rugo HS, Delord JP, Im SA, et al. Preliminary efficacy and safety of pembrolizumab (MK-3475) in patients with PD-L1-positive, estrogen receptor-positive (ER+)/HER2-negative advanced breast cancer enrolled in KEYNOTE-028[J]. Cancer Res, 2016, 76(4 suppl):abstr S5-07. https://www.researchgate.net/publication/303396698_Abstract_S5-07_Preliminary_efficacy_and_safety_of_pembrolizumab_MK-3475_in_patients_with_PD-L1-positive_estrogen_receptor-positive_ERHER2-negative_advanced_breast_cancer_enrolled_in_KEYNOTE-028
[30]	Dirix LY, Takacs I, Nikolinakos P, et al. Avelumab (MSB0010718C), an antiPD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase Ib JAVELIN solid tumor trial[J]. Cancer Res, 2016, 76 (suppl 4):abstr S1-04. http://www.oncologynurseadvisor.com/sabcs-annual-symposium-2015/avelumab-demonstrated-clinical-activity-in-subset-of-patients-with-metastatic-breast-cancer/article/458839/